Person:
AVCI, BERRİN

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

AVCI

First Name

BERRİN

Name

Search Results

Now showing 1 - 10 of 24
  • Publication
    Evaluation of endometrioma pathophysiology and related ovarian damage by PTEN / AKT apoptosis signaling pathway
    (Elsevier Science, 2020-09-01) Şen, Furkan; Aslan, Kiper; Kuşpınar, Göktan; Çakır, Cihan; Kasapoglu, Işıl; Avcı, Berrin; Uncu, Gürkan; ŞEN, HAMZA FURKAN; ASLAN, MÜNİR KİPER; KUŞPINAR, GÖKTAN; ÇAKIR, CİHAN; KASAPOĞLU, IŞIL; AVCI, BERRİN; UNCU, GÜRKAN; Tıp Fakültesi; Kadın Hastalıkları ve Doğum Ana Bilim Dalı; 0000-0002-9277-7735; 0000-0002-8332-7353; AAH-5119-2021; AAT-3479-2021; HTQ-5866-2023; AER-7173-2022; AAH-9694-2021; AAH-5249-2021; KEU-2073-2024; CXJ-7203-2022; ELU-2357-2022
  • Publication
    The efficacy and molecular mechanism of dehydroepiandrosterone in diminished ovarian reserve
    (Oxford Univ Press, 2020-07-01) Avcı, Berrin; AVCI, BERRİN; Çakır, C.; Kuşpınar, Göktan; KUŞPINAR, GÖKTAN; Işıklar, S.; Aslan, Kiper; ASLAN, MÜNİR KİPER; Kasapoğlu, I.; Uncu, Gürkan; UNCU, GÜRKAN; Tıp Fakültesi; 0000-0002-9277-7735; HTQ-5866-2023; AAH-9694-2021; AAH-5119-2021; ABE-6685-2020; AER-7173-2022; AAT-3479-2021
  • Publication
    Fertilisation and early embryonic development of immature and rescue in vitro-matured sibling oocytes
    (Taylor & Francis, 2020-01-16) Avcı, Berrin; Kasapoğlu, Işıl; Çakir, Cihan; Özbay, Aysun; Ata, Barış; Uncu, Gürkan; AVCI, BERRİN; KASAPOĞLU, IŞIL; ÇAKIR, CİHAN; Özbay, Aysun; UNCU, GÜRKAN; Tıp Fakültesi; Histoloji ve Embriyoloji Ana Bilim Dalı; 0000-0002-8332-7353; 0000-0001-8135-5468; AAT-3479-2021; GQR-0770-2022; AAH-5249-2021; CXJ-7203-2022 ; ABE-6685-2020
    The objective of this study was to assess the effect of rescue in vitro maturation and immediate intracytoplasmic sperm injection (ICSI) application on fertilisation success and early embryonic development of metaphase I (MI) oocytes. This was a retrospective cohort study including 2425 sibling oocytes in 259 ICSI cycles. ICSI was performed on 104 GV (germinal vesicle) oocytes which had reached the metaphase II (MII) stage (Group 1) and 231 MI oocytes which had reached the MII stage (Group 2) following IVM (in vitro maturation). Immediate ICSI was applied following oocyte aspiration on 292 MI stage (Group 3) and 1798 MII stage oocytes (Group 4). Normal fertilisation rates in Groups 1, 2, 3 and 4 were 51.9%, 39%, 30.1% and 59.5%, respectively. The rates of blastocyst development per oocyte and per zygote were calculated as 3.8%, 3.0%, 6.8%, 14.1% and 7.4%, 7.7%, 22.7%, 23.6% for Groups 1, 2, 3 and 4, respectively. The blastocyst development rate was significantly higher in the MI-ICSI group compared with other immature oocytes. Even though performing ICSI on the oocytes at the MI stage on the day of oocyte aspiration resulted in lower fertilisation rates, it was associated with significantly higher rates of blastocyst development.
  • Publication
    Amh levels may predict for mullerian anomalies and pregnancy outcomes patients with pcos.
    (Elsevier, 2020-09-01) Aslan, Kiper; ASLAN, MÜNİR KİPER; Albayrak, Özge; Bilgiç, Kübra Özlem; BİLGİÇ, KÜBRA ÖZLEM; Kasapoglu, Işıl; KASAPOĞLU, IŞIL; Avci, Berrin; AVCI, BERRİN; Uncu, Gurkan; UNCU, GÜRKAN; Tıp Fakültesi; Kadın Hastalıkları ve Doğum Ana Bilim Dalı; 0000-0002-9277-7735; AAH-9694-2021; AER-7173-2022; AAT-3479-2021
  • Publication
    The kisspeptin and kisspeptin receptor in follicular microenvironment: Is that really necessary for oocyte maturation and fertilisation?
    (Taylor & Francis Inc, 2022-08-19) Kuşpinar, Göktan; KUŞPINAR, GÖKTAN; Çakır, Cihan; ORAL, HALUK BARBAROS; ÇAKIR, CİHAN; KASAPOĞLU, IŞIL; Sarıbal, Seda; BUDAK, FERAH; Budak, Ferah; Avcı, Berrin; Uncu, Gürkan; UNCU, GÜRKAN; AVCI, BERRİN; Tıp Fakültesi; İmmunoloji Ana Bilim Dalı; 0000-0002-8332-7353; 0000-0001-7625-9148; IZP-9398-2023; AAH-5249-2021; F-4657-2014; HTQ-5866-2023
    The aim of this study was to determine whether Kisspeptin and Kisspeptin receptor in the follicular microenvironment is necessary for human oocyte maturation and fertilisation. The cumulus cell (CC) and follicle fluids (FF) obtained from the first aspirated follicles (n = 52) from 32 patients were divided into three groups considering nuclear maturation and fertilisation results of oocytes: (1) Metaphase I or germinal vesicle stage oocytes (incomplete nuclear maturation, n = 10), (2) unfertilised metaphase II oocytes (incomplete cytoplasmic maturation, n = 16), and (3) fertilised metaphase II oocytes (completed nuclear-cytoplasmic maturation, n = 26). The gene expression levels were assessed by RT-PCR. The levels of Kisspeptin (KISS1) and Kisspeptin receptor (KISS1R) were measured by ELISA. There were no significant efficacy KISS1 and KISS1R gene expressions in cumulus cells in terms of oocyte nuclear maturation stage (Group 1, vs Group 2 + Group 3) (respectively p = .49; p = .45). In terms of the cytoplasmic maturation stage (Group 2, vs Group 3); KISS1 and KISS1R expressions in CCs were comparable (respectively p = .07; p = .08). In FFs, KISS1 and KISS1R concentrations were similar between all groups (respectively p = .86; p = .26). In conclusion, the relative KISS1 and KISS1R expressions in CC and also KISS1 and KISS1R level of FF were independent of oocytes nuclear and/or cytoplasmic maturation. Impact statement What is already known on this subject? It has been demonstrated that Kisspeptin is an essential regulator of reproductive function and plays a key role in the modulation of GnRH secretion and gonadotropin release. Still, no information is available about the link between gene expression or concentration in the follicular microenvironment and oocyte development. What do the results of this study add? The study has shown that the relative Kisspeptin (KISS1) and Kisspeptin receptor (KISS1R) and expressions in cumulus cell (CC) and also KISS1 and KISS1R levels of follicle fluids (FF) were independent of oocytes nuclear and/or cytoplasmic maturation. What are the implications of these findings for clinical practice and/or further research? Based on the findings, it is difficult to establish a concept that kisspeptin can directly induce oocyte maturation. Nevertheless, to confirm these findings, further studies with a larger sample size are needed.
  • Publication
    Which is more predictive ovarian sensitivity marker if there is discordance between serum anti-Mullerian hormone levels and antral follicle count? A retrospective analysis
    (Taylor & Francis Inc, 2022-01-07) Aslan, Kiper; Kasapoğlu, Işıl; Çakır, Cihan; Koç, Meltem; Çelenk, Murat Deniz; Ata, Barış; Avcı, Berrin; Uncu, Gürkan; ASLAN, MÜNİR KİPER; KASAPOĞLU, IŞIL; ÇAKIR, CİHAN; KOÇ ÇAKAR, MELTEM; ÇELENK, MURAT DENİZ; AVCI, BERRİN; UNCU, GÜRKAN; Tıp Fakültesi; Kadın Hastalıkları ve Doğum Ana Bilim Dalı; 0000-0002-9277-7735; 0000-0002-8332-7353; 0000-0001-6456-8779; AAT-3479-2021; AAH-5249-2021; AER-7173-2022; CXJ-7203-2022; EPE-7010-2022; ELU-2357-2022
    This retrospective study aims to determine the more predictive ovarian reserve marker when there is discordance between anti-Mullerian hormone (AMH) and antral follicle count (AFC) in patients with diminished ovarian reserve (DOR). Patients who underwent ICSI because of DOR were divided into three groups. Group 1: patients with low AMH (<1.1 ng/ml) and AFC (n < 7), group 2: patients with low AMH (<1.1 ng/ml) and normal AFC (n >= 7) and group 3: patients with normal AMH (>= 1.1 ng/dl) and low AFC (n < 7). Demographic values, follicle output rate (FORT) score and follicle to oocyte index (FOI) score of the groups were compared. Totally, 662 cycles were enrolled in the study. There were 418 cycles in group 1, 167 cycles in group 2 and 77 cycles in group 3. As the primary result, FORT and FOI scores were higher in group 3 than the other two groups. Median FORT Score with quartiles: group 1: 100 (66-150), group 2: 71 (57-100), group 3: 136 (96-200), p<.01 - median FOI score with quartiles: group 1: 83 (50-140), group 2: 71 (40-100), group 3: 116 (66-216), p<.01. In conclusion, serum AMH level has more predictive value for stimulation success if there is discordance with AFC.Impact Statement What is already known on this subject? Female age, serum Anti-Mullerian Hormone (AMH) levels, and antral follicle count (AFC) are commonly used to assess ovarian reserve and predict response to ovarian stimulation. AMH and AFC are both positively correlated with ovarian reserve. What do the results of this study add? If there is discordance between AFC and AMH in patients with diminished ovarian reserve (DOR), the ovarian response is better in patients with high AMH and low AFC than the patients with low AMH and high AFC. What are the implications of these findings for clinical practice and/or further research? It is important to assess both AFC and AMH before controlled ovarian hyperstimulation, to predict ovarian response in DOR patients, rather than assessing AFC or AMH alone.
  • Publication
    Low molecular weight heparin-aspirin-prednisolone combination does not increase the live birth rate in recurrent implantation failure: A retrospective cohort study
    (Springer Heidelberg, 2023-05-30) Aslan, Kiper; Kasapoğlu, Işıl; Çınar, Ceren; Çakır, Cihan; Avcı, Berrin; Uncu, Gürkan; ASLAN, MÜNİR KİPER; KASAPOĞLU, IŞIL; ÇINAR, CEREN; ÇAKIR, CİHAN; AVCI, BERRİN; UNCU, GÜRKAN; Tıp Fakültesi; Kadın Hastalıkları ve Doğum Ana Bilim Dalı; 0000-0002-9277-7735; 0000-0002-8332-7353; AER-7173-2022; CXJ-7203-2022; IUD-1217-2023; AAH-5249-2021; ELU-2357-2022; AAT-3479-2021
    This study investigates the triple combination of adjuvants (low molecular weight heparin (LMWH)-aspirin-prednisolone) whether it improves the live birth rates of IVF&ICSI patients with previous implantation failure. This retrospective study included 1095 patients with >2 failed either fresh or frozen single embryo transfer cycles between 2014 Jan and 2021 Jan. Patients were divided into two subgroups. Group A consisted of patients with only vaginal progesterone for luteal phase support. Group B consisted of patients with triple (daily subcutaneous LMWH, daily 150 mg aspirin, and daily 16 mg prednisolone) luteal phase supplementation to vaginal progesterone. Demographic parameters, cycle characteristics, embryology, and pregnancy outcomes were compared, and the study's primary outcome was the live birth rate. Demographic parameters were similar between the groups. Positive b-hCG, miscarriage, and live birth rates were similar between groups as Group A vs. Group B, positive b-hCG 30.8% (190/617) vs. 35.4% (169/478), miscarriage rates 4.4% (27/617) vs. 6.7% (32/478), and live birth rates 20.4% (126/617) vs. 23.8% (114/478), respectively. When patients were stratified according to previous failures, live birth rates were still similar. Pregnancy outcomes were significantly improved in only patients with diminished ovarian reserve (Group A vs. Group B, positive b-hCG 24.2% vs. 34.3%, live birth rate 12.1% vs. 21.9%, p < 0.01). Whether the embryo transfer was fresh or frozen-thawed did not affect the results. A combined supplementation of LMWH, aspirin, and prednisolone in the luteal phase does not improve live birth rates of IVF&ICSI patients with previous implantation failure except potentially for patients with diminished ovarian reserve.
  • Publication
    Scheduling gnrh antagonist cycles by a short course of oral estradiol administration during early follicular phase: A comparative study with non-scheduled cycles
    (Taylor & Francis Ltd, 2015-06-01) Aslan, Kiper; ASLAN, MÜNİR KİPER; UNCU, GÜRKAN; Avci, Berrin; AVCI, BERRİN; Uncu, Gürkan; Saribal, Seda; Ata, Barış; Tıp Fakültesi; Kadın Hastalıkları Ana Bilim Dalı; 0000-0002-9277-7735; 0000-0003-1106-3747; C-8049-2013; AAT-3479-2021; AER-7173-2022; AAH-9694-2021; ABE-6685-2020
    This hypothesis generating study investigated whether GnRH antagonist cycles can be scheduled by a short course of oral estradiol administration during the follicular phase without impairing treatment outcome. Thirty-five women who underwent follicular phase estrogen scheduling (ES) of GnRH antagonist cycles were retrospectively matched for age and number of prior failed cycles with 35 women who underwent unscheduled GnRH antagonist cycles. ES group was given 6 mg/day estradiol orally from cycle day 2 until (including) one day before the scheduled start of stimulation. Gonadotropins were started on cycle days 2-3 in the control group. Flexible GnRH antagonist protocol was employed in both groups. ES group received estradiol for a median of 5 days. Total gonadotropin consumption was similar but one more GnRH antagonist injection was required in the ES group. Endometrial thickness on the day of hCG injection was increased in the ES group (12 versus 10 mm, p<0.01). Number of oocytes, metaphase II oocytes and transferred embryos were similar. Embryo implantation rates were 44.8% versus 34.4% (p=0.3), and clinical pregnancy rates were 48.6% versus 37.1%, (p=0.33) in the ES and control groups, respectively. All women in the ES group had oocyte retrieval and embryo transfer within the desired period.
  • Publication
    Effect of embryo morphology on maternal serum β-hCG level in pregnancies resulting from a fresh single cleavage embryo and a fresh single blastocyst
    (Oxford Univ Press, 2018-07-01) Kuşpınar, Göktan; Kasapoğlu, Işıl; Sarıbal, Seda; Uncu, Gürkan; Avcı, Berrin; KUŞPINAR, GÖKTAN; KASAPOĞLU, IŞIL; Sarıbal, Seda; UNCU, GÜRKAN; AVCI, BERRİN; Sağlık Bilimleri Enstitüsü; Kadın Hastalıkları ve Doğum Ana Bilim Dalı; 0000-0002-0338-8368; AAH-5119-2021; HTQ-5866-2023; AAT-3479-2021; ABE-6685-2020; CXJ-7203-2022; FTW-2214-2022
  • Publication
    Luteal oestradiol for patients with serum oestradiol levels lower than expected per oocyte
    (Taylor, 2021-03-15) Kasapoğlu, Işıl; Düzok, Nergis; Şen, Esra; Çakır, Cihan; Avcı, Berrin; Uncu, Gürkan; KASAPOĞLU, IŞIL; DÜZOK, NERGİS; Şen, Esra; ÇAKIR, CİHAN; AVCI, BERRİN; UNCU, GÜRKAN; Tıp Fakültesi; Histoloji ve Embriyoloji Ana Bilim Dalı; 0000-0002-8332-7353; AAT-3479-2021; AAH-5249-2021; CXJ-7203-2022; JLC-5688-2023; FVL-9509-2022; ELU-2357-2022
    Although the efficiency of progesterone in providing luteal phase support has been established, the role of oestradiol supplementation during the luteal phase remains controversial. We evaluated pregnancy outcomes of patients who had a ratio of serum E2 levels on the hCG day to the number of oocytes retrieved (oestradiol/oocyte ratio - EOR) levels of <100 pg/ml by supporting them with additional oestradiol during the luteal phase. In total, 150 patients with an EOR < 100 pg/ml of oestradiol undergoing antagonist intracytoplasmic sperm injection (ICSI) cycles were randomly assigned into two groups to receive either oral oestradiol (4 mg/d) plus vaginal progesterone (90 mg, 2 x 1/day) (group 1) or vaginal progesterone (90 mg, 2 x 1/d) alone (group 2). Implantation rate following transfer of a single embryo did not differ between the two groups (group 1 = 33.3%; group 2 = 34.9%; p = 0.85). Similarly, both groups gave comparable clinical pregnancy rates per embryo transfer with 31.7% in group 1 compared with 28.6% in group 2 (p = 0.69). In conclusion the study suggests that the addition of 4 mg oral E2 to progesterone does not increase the probability of pregnancy.